Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This study in patients with relapsed/refractory follicular lymphoma who have undergone at
least 3 lines of therapy. Patients will receive abexinostat 80 mg (4 × 20 mg tablets) twice a
day (BID) in a "one week on, one week off" schedule.